A28 Therapeutics, a cutting-edge biopharma company, secured $25 million in Series A funding through an exclusive London investment event expertly organized by Troy Group. By crafting a high-impact event strategy, bringing together top-tier investors, and ensuring an engaging presentation of A28’s groundbreaking oncology solutions, Troy Group played a key role in positioning the company for success in its next phase of clinical and research advancements.